Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study.

In a sensitivity analysis excluding GC patients who switched from cisplatin to carboplatin, the favorable associations observed in the main overlap-weighted analysis were attenuated and did not reach statistical significance.

also in 111,027 other papers